Medtronic III: The best method is yet to come?
The recent decision from the U.S. Tax Court results in an outcome that is anything but tidy. What happened? Read our commentary in this edition of Insights: MEDTRONIC PART DEUX: THE BEST METHOD IS YET TO COME? The purpose of the most recent decision in the Medtronic saga[1] extends and refines the prior analysis of one of five connected controlled transactions within Medtronic’s controlled group of multinational medical device producers and suppliers. The transactions may be described as follows: The first two transactions – license of manufacturing intangible property and license of trademarks – were the main subject of a period of examination controversy that concluded with the I.R.S. adjusting the royalty income of the U.S. Medtronic licensor for tax years 2005 and 2006. The adjustments included additional income necessary for the royalty to be arm’s length as determined under the comparable profits method (“C.P.M.”)… Read More »Medtronic III: The best method is yet to come?